Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C38690
http://purl.obolibrary.org/obo/NCIT_C38690
|
|---|---|
| Preferred Name | Muparfostat |
| Definitions |
A mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic activity. Muparfostat inhibits the endo-beta-D-glucuronidase heparanase, which may interfere with the heparanase-mediated degradation of heparan-sulfate proteoglycans in extracellular matrices, an important step in the metastatic process. This agent may also bind with high affinity to the heparan sulfate-binding domains of vascular endothelial growth factor (VEGF) and fibroblast growth factors 1 and 2, thereby reducing their functional activities and inhibiting VEGF and FGF stimulation of tumor angiogenesis. Increased heparanase activity has been implicated in tumor angiogenesis and metastasis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic activity. Muparfostat inhibits the endo-beta-D-glucuronidase heparanase, which may interfere with the heparanase-mediated degradation of heparan-sulfate proteoglycans in extracellular matrices, an important step in the metastatic process. This agent may also bind with high affinity to the heparan sulfate-binding domains of vascular endothelial growth factor (VEGF) and fibroblast growth factors 1 and 2, thereby reducing their functional activities and inhibiting VEGF and FGF stimulation of tumor angiogenesis. Increased heparanase activity has been implicated in tumor angiogenesis and metastasis. |
|---|---|
| prefLabel | Muparfostat
|
| label | Muparfostat
|
| PDQ_Closed_Trial_Search_ID | 339562
|
| code | C38690
|
| prefixIRI | NCIT:C38690
|
| in_subset |
See more
See less
|
| Display_Name | Muparfostat
|
| Preferred_Name | Muparfostat
|
| FDA_UNII_Code | P2BKS6T40H
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Muparfostat
|
| CAS_Registry | 1020105-89-8
|
| NCI_Drug_Dictionary_ID | 339562
|
| Legacy Concept Name | PI-88
|
| type | |
| ALT_DEFINITION | A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antiangiogenesis agents.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 339562
|
| Accepted_Therapeutic_Use_For | Malignant melanoma
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C0769628
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |